Leukemia

Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition.  36:2621-2633. 2022

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.  36:1720-1748. 2022

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.  36:1703-1719. 2022

Isocitrate dehydrogenase mutations are associated with altered IL-1β responses in acute myeloid leukemia.  36:923-934. 2022

Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232.  36:648-655. 2022

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.  36:877-880. 2022

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients 2022

Microenvironmental CXCL12 deletion enhances Flt3-ITD acute myeloid leukemia stem cell response to therapy by reducing p38 MAPK signaling 2022

UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia 2022

Metabolic alterations mediated by STAT3 promotes drug persistence in CML.  35:3371-3382. 2021

HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions.  35:3040-3043. 2021

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.  35:3278-3281. 2021

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.  35:2854-2861. 2021

Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (Leukemia, (2021), 35, 7, (2076-2085), 10.1038/s41375-021-01213-5).  35:2140. 2021

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.  35:2076-2085. 2021

Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (Leukemia, (2021), 35, 5, (1279-1290), 10.1038/s41375-021-01177-6).  35:1527. 2021

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631.  35:1279-1290. 2021

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.  35:18-30. 2021

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.  34:3215-3227. 2020

Simplified frailty assessment tools: are we really capturing frailty or something else?.  34:1967-1969. 2020

Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905.  34:1006-1016. 2020

Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21.  34:358-368. 2020

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.  33:2599-2609. 2019

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.  33:2266-2275. 2019

Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically.  33:1620-1634. 2019

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.  33:1273-1277. 2019

Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.  33:771-775. 2019

Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.  33:371-378. 2019

Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.  33:554-558. 2019

Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.  32:2706-2709. 2018

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.  32:2536-2545. 2018

Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.  32:2352-2362. 2018

Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).  32:1370-1379. 2018

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: An analysis of Alliance studies.  32:1338-1348. 2018

Treatment approaches and outcomes in plasmacytomas: Analysis using a national dataset.  32:1414-1420. 2018

Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.  32:575-587. 2018

Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). 2017

The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.  31:2503-2514. 2017

The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.  31:2267-2271. 2017

The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.  31:2211-2218. 2017

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.  31:1648-1650. 2017

Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.  31:1450-1453. 2017

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.  31:1278-1285. 2017

No evidence for microsatellite instability in acute myeloid leukemia.  31:1474-1476. 2017

CARMA1 is a novel regulator of T-ALL disease and leukemic cell migration to the CNS..  31:255-258. 2017

Adult acute myeloid leukemia with trisomy 11 as the sole abnormality is characterized by the presence of five distinct gene mutations: MLL-PTD, DNMT3A, U2AF1, FLT3-ITD and IDH2.  30:2254-2258. 2016

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.  30:2214-2220. 2016

Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.  30:2080-2083. 2016

MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: A Children's Oncology Group Study.  30:1909-1912. 2016

Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.  30:1779-1780. 2016

Clinical features and gene-and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).  30:1586-1589. 2016

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: A report from the Children's Oncology Group.  29:2424-2426. 2015

Early mortality in multiple myeloma.  29:1616-1618. 2015

Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.  29:567-575. 2015

The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.  29:233-237. 2015

Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.  28:428-430. 2014

Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: A report from SWOG and MD Anderson.  28:289-292. 2014

An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome.  28:1015-1021. 2014

GAS6 expression identifies high-risk adult AML patients: Potential implications for therapy.  28:1252-1258. 2014

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031.  28:1467-1471. 2014

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: Opportunities for therapeutic intervention.  28:15-33. 2014

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: Results from children's oncology group study AALL0031.  28:964-967. 2014

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.  28:1754-1758. 2014

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.  27:2023-2031. 2013

Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies..  27:1263-1274. 2013

Conditional survival and cause-specific mortality after autologous hematopoietic cell transplantation for hematological malignancies.  27:1139-1145. 2013

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: A SWOG report.  27:238-241. 2013

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia.  26:1713-1717. 2012

Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.  25:1365-1368. 2011

GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia..  25:1135-1146. 2011

Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T-cell acute lymphoblastic leukemia.  25:1042-1046. 2011

Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles.  25:1555-1563. 2011

HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells.  25:23-31. 2011

Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells.  25:305-312. 2011

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.  25:463-472. 2011

Late effects in survivors of acute leukemia treated with hematopoietic cell transplantation: A report from the Bone Marrow Transplant Survivor Study.  24:2039-2047. 2010

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.  24:1299-1301. 2010

Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.  24:779-787. 2010

A robust xenotransplantation model for acute myeloid leukemia.  23:2109-2117. 2009

Targeting the leukemic stem cell: The Holy Grail of leukemia therapy.  23:25-42. 2009

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.  22:686-707. 2008

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.  22:748-755. 2008

HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia.  22:1161-1169. 2008

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.  22:708-722. 2008

The bone marrow niche: Habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites.  22:941-950. 2008

Gene expression overlap affects karyotype prediction in pediatric acute lymphoblastic leukemia [17].  21:1341-1344. 2007

Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma [7].  21:184-187. 2007

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies [4].  20:1295-1297. 2006

Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells.  20:1254-1260. 2006

High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: A Children's Oncology Group (COG) initiative.  19:734-740. 2005

Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support.  19:98-102. 2005

No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities.  19:557-563. 2005

Nonproliferating CML CD34⁺ progenitor are resistant to apoptosis induced by a wide range of proapoptotic stimuli.  19:1034-1041. 2005

Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): A review of four consecutive childhood AML trials conducted between 1981 and 2000.  19:2101-2116. 2005

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.  18:189-218. 2004

RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia.  18:685-692. 2004

Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome.  18:693-702. 2004

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.  17:700-706. 2003

B-cell development in the presence of the MLL/AF4 oncoprotein proceeds in the absence of HOX A7 and HOX A9 expression.  17:2454-2459. 2003

Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.  17:2358-2382. 2003

AML1 gene over-expression in childhood acute lymphoblastic leukemia.  16:658-668. 2002

AML1 gene over-expression in childhood acute lymphoblastic leukemia..  16:658-668. 2002

AML1 gene over-expression in childhood acute lymphoblastic leukemia.  16:658-668. 2002

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).  16:1627-1636. 2002

T(7;12)(q36;p13) and t(7;12)(q32;p13) - Translocations involving ETV6 in children 18 months of age or younger with myeloid disorders.  15:915-920. 2001

Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): A Pediatric Oncology Group study.  14:238-240. 2000

Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells.  14:2095-2102. 2000

Prognostic factors in children and adolescents with acute myeloid leukemia (exluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.  14:1201-1207. 2000

Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: A pediatric oncology group study.  14:1570-1576. 2000

Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience.  13:135-141. 1999

Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL, a Pediatric Oncology Group (POG) study.  13:1696-1707. 1999

Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.  12:1708-1717. 1998

Molecular analysis of the PML/RARα chimeric gene in pediatric acute promyelocytic leukemia.  10:1296-1302. 1996

Long-term follow-up of a randomized post-induction therapy trial in acute myeloeenous leukemia (A Southeastern Cancer Study Group Trial).  9:1456-1460. 1995

T lymphocytes cultured from chronic myelogenous leukemia bone marrow suppress autologous hematopoietic progenitors.  9:1006-1012. 1995

A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.  8:1847-1853. 1994

Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.  8:1124-1130. 1994

Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: A pediatric oncology group study.  7:2064-2068. 1993

Childhood acute lymphoblastic leukemia with both t(1;19) and t(9;22).  6:535-540. 1992

The non-random dic(9;12) translocation in acute lymphoblastic leukemia is associated with B-progenitor phenotype and an excellent prognosis.  6:703-707. 1992

t(12;17)(p13;q21) in early pre-B acute lymphoid leukemia.  6:251-255. 1992

Heterogeneity of the breakpoint localization in malignant cells with a 9p11 chromosomal abnormality.  5:468-472. 1991